IMNM
Immunome, Inc. NASDAQ Listed Oct 2, 2020$25.75
+2.71%
vs $25.07
Mkt Cap $2.2B
52w Low $9.77
79.7% of range
52w High $29.83
50d MA $25.36
200d MA $22.69
P/E (TTM)
-10.1x
EV/EBITDA
—
P/B
3.5x
Debt/Equity
0.0x
ROE
-33.5%
P/FCF
-11.2x
RSI (14)
39.90
ATR (14)
$1.07
Beta
2.14
50d MA
$25.36
200d MA
$22.69
Avg Volume
1.1M
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
665 Stockton Drive · Bothell, PA 19341 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | AMC | -0.51 | -0.65 | -26.5% | 26.25 | -3.9% | +6.6% | -5.6% | +3.0% | +0.7% | +0.6% | — |
| May 12, 2026 | AMC | -0.60 | -0.48 | +20.0% | 22.69 | +3.1% | -2.2% | -0.8% | -5.2% | -4.7% | -1.2% | — |
| Mar 3, 2026 | AMC | -0.59 | -0.75 | -27.1% | 21.54 | +2.1% | +4.5% | -7.0% | +0.4% | +1.4% | +2.5% | — |
| Nov 6, 2025 | AMC | -0.57 | -0.65 | -14.0% | 15.50 | -0.3% | -1.7% | +7.9% | +6.6% | -0.5% | -5.3% | — |
| Aug 6, 2025 | AMC | -0.52 | -0.50 | +3.8% | 10.46 | +2.4% | -5.6% | -1.8% | -0.3% | +2.6% | +1.0% | — |
| May 12, 2025 | AMC | -0.66 | -0.52 | +21.2% | 7.94 | +5.4% | -0.4% | +0.8% | +0.4% | +0.7% | -0.6% | — |
| Mar 19, 2025 | AMC | -0.68 | -0.84 | -23.5% | 8.57 | -1.8% | +1.1% | -5.5% | -0.4% | -14.7% | +2.0% | — |
| Nov 13, 2024 | AMC | -0.60 | -0.78 | -30.0% | 11.59 | -0.2% | -3.9% | -11.1% | -4.6% | -0.5% | -0.6% | — |
| Aug 12, 2024 | AMC | -0.38 | -0.49 | -28.9% | 12.64 | +0.8% | +7.0% | -0.2% | +3.3% | -3.0% | +5.7% | — |
| May 14, 2024 | AMC | -0.80 | -0.34 | +57.5% | 14.72 | +1.4% | +0.5% | -2.7% | -4.0% | -0.2% | -1.1% | — |
| Mar 28, 2024 | AMC | -0.28 | -0.54 | -92.9% | 24.68 | +0.5% | -10.4% | -3.3% | +1.0% | -6.2% | +0.0% | — |
| Nov 9, 2023 | AMC | -0.17 | -0.36 | -111.8% | 8.56 | -1.4% | -5.5% | +1.9% | -2.7% | -0.9% | -0.3% | — |
| Aug 9, 2023 | AMC | -0.16 | -0.46 | -187.5% | 7.04 | +0.7% | +0.1% | +3.0% | -1.9% | +4.5% | -2.0% | — |
| May 5, 2023 | AMC | 0.59 | -0.35 | -159.3% | 5.40 | +0.9% | +6.7% | +8.5% | +0.8% | +1.0% | +7.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 21 | Alliance Global Partners | Initiates | Buy | $32 | $23.97 | $24.63 | +2.8% | +4.6% | — | — | — | — |
| May 28 | Barclays | Initiates | Overweight | $36 | $22.11 | $22.38 | +1.2% | +1.9% | -3.1% | -4.8% | -6.9% | +2.4% |
| Mar 4 | Stephens & Co. | Maintains | Overweight → Overweight | — | $21.54 | $22.00 | +2.1% | +4.5% | -7.0% | +0.4% | +1.4% | +2.5% |
| Mar 4 | Craig-Hallum | Maintains | Buy → Buy | — | $21.54 | $22.00 | +2.1% | +4.5% | -7.0% | +0.4% | +1.4% | +2.5% |
| Jan 15 | Wedbush | Maintains | Outperform → Outperform | — | $20.76 | $20.61 | -0.7% | +10.1% | -1.9% | +6.6% | +4.1% | +3.8% |
| Dec 16 | Evercore ISI | Maintains | Outperform → Outperform | — | $22.64 | $22.88 | +1.1% | +3.7% | -15.8% | +0.9% | +7.5% | +2.8% |
| Dec 16 | Guggenheim | Maintains | Buy → Buy | — | $22.64 | $22.88 | +1.1% | +3.7% | -15.8% | +0.9% | +7.5% | +2.8% |
| Dec 16 | Lake Street | Maintains | Buy → Buy | — | $22.64 | $22.88 | +1.1% | +3.7% | -15.8% | +0.9% | +7.5% | +2.8% |
| Nov 17 | Stephens & Co. | Maintains | Overweight → Overweight | — | $17.14 | $17.71 | +3.3% | +5.8% | -1.5% | -1.0% | -1.0% | +5.8% |
| Aug 25 | Guggenheim | Maintains | Buy → Buy | — | $10.30 | $10.30 | +0.0% | -3.7% | +2.4% | -2.1% | -0.5% | -3.9% |
| Aug 7 | JP Morgan | Maintains | Overweight → Overweight | — | $10.46 | $10.71 | +2.4% | -5.6% | -1.8% | -0.3% | +2.6% | +1.0% |
| Mar 20 | Wedbush | Maintains | Outperform → Outperform | — | $8.57 | $8.42 | -1.8% | +1.1% | -5.5% | -0.4% | -14.7% | +2.0% |
| Mar 20 | Guggenheim | Maintains | Buy → Buy | — | $8.57 | $8.42 | -1.8% | +1.1% | -5.5% | -0.4% | -14.7% | +2.0% |
| Mar 20 | Stephens & Co. | Maintains | Overweight → Overweight | — | $8.57 | $8.42 | -1.8% | +1.1% | -5.5% | -0.4% | -14.7% | +2.0% |
| Nov 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.59 | $11.57 | -0.2% | -3.9% | -11.1% | -4.6% | -0.5% | -0.6% |
| Oct 25 | Wedbush | Maintains | Outperform → Outperform | — | $12.01 | $12.10 | +0.7% | +0.8% | +2.6% | -1.9% | +0.0% | -6.0% |
| Aug 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.64 | $12.74 | +0.8% | +7.0% | -0.2% | +3.3% | -3.0% | +5.7% |
| Aug 13 | Wedbush | Maintains | Outperform → Outperform | — | $12.64 | $12.74 | +0.8% | +7.0% | -0.2% | +3.3% | -3.0% | +5.7% |
| Apr 1 | Wedbush | Maintains | Outperform → Outperform | — | $24.68 | $24.81 | +0.5% | -10.4% | -3.3% | +1.0% | -6.2% | +0.0% |
| Jan 23 | Wedbush | Maintains | Outperform → Outperform | — | $15.65 | $15.92 | +1.7% | -4.2% | +2.2% | +7.0% | +6.6% | +10.4% |
| Mar 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.69 | $5.63 | -1.1% | -0.7% | -0.9% | -4.1% | -3.9% | -1.4% |
| Mar 17 | Chardan Capital | Maintains | Buy → Buy | — | $5.14 | $5.02 | -2.4% | +10.6% | -0.7% | -0.9% | -4.1% | -3.9% |
| Oct 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.85 | $23.30 | +2.0% | +2.6% | -5.0% | +2.8% | -4.1% | +3.1% |
| Oct 27 | Chardan Capital | Maintains | Buy → Buy | — | $12.20 | $12.49 | +2.4% | +2.5% | -8.0% | +0.4% | -1.7% | -3.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Higgins Jack | Chief Scientific Officer | Sell | 13,200 | $25.32 | $334K | 65,050 | -2.05% | +2.71% |
| Aug 12, 2026 | Barchas Isaac | — | Sell | 11,048 | $27.25 | $301K | 92,211 | -5.61% | +8.22% |
| Aug 11, 2026 | Barchas Isaac | — | Sell | 62,291 | $26.23 | $1.6M | — | -5.61% | +8.22% |
| Aug 10, 2026 | Barchas Isaac | — | Sell | 10,125 | $26.07 | $264K | 62,291 | -5.61% | +8.22% |
| Aug 7, 2026 | Barchas Isaac | — | Sell | 15,248 | $26.06 | $397K | 72,416 | +2.18% | +0.74% |
| Aug 6, 2026 | Barchas Isaac | — | Sell | 20,840 | $26.06 | $543K | 87,664 | +2.18% | +0.74% |
| Aug 4, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Sell | 90,616 | $25.09 | $2.3M | — | -3.06% | -5.61% |
| Jul 7, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Sell | 1,092 | $25.00 | $27K | — | -3.39% | -3.14% |
| Jul 7, 2026 | Barchas Isaac | — | Sell | 16,906 | $24.20 | $409K | 108,504 | -1.56% | -0.92% |
| Jul 6, 2026 | Barchas Isaac | — | Sell | 83,094 | $24.11 | $2.0M | 125,410 | -1.56% | -0.92% |
| Jul 2, 2026 | Lechleider Robert | Chief Medical Officer | Sell | 16,072 | $23.44 | $377K | 15,805 | -1.56% | -0.92% |
| Jul 2, 2026 | Lechleider Robert | Chief Medical Officer | Sell | 16,214 | $22.76 | $369K | 31,877 | -1.56% | -0.92% |
| Jul 2, 2026 | Lechleider Robert | Chief Medical Officer | Sell | 22,714 | $21.95 | $499K | 48,091 | -1.56% | -0.92% |
| Jul 2, 2026 | Barchas Isaac | — | Sell | 24,335 | $23.33 | $568K | 208,504 | +1.23% | -3.39% |
| Jul 2, 2026 | Barchas Isaac | — | Sell | 75,665 | $22.35 | $1.7M | 232,839 | +1.23% | -3.39% |
| Jun 30, 2026 | Barchas Isaac | — | Sell | 101,050 | $21.12 | $2.1M | 308,504 | +1.23% | -3.39% |
| Jun 25, 2026 | Lechleider Robert | Chief Medical Officer | Sell | 14,420 | $20.66 | $298K | 15,805 | +0.71% | +2.05% |
| Jun 25, 2026 | Lechleider Robert | Chief Medical Officer | Sell | 40,580 | $19.56 | $794K | 30,225 | +0.71% | +2.05% |
| Jun 15, 2026 | Rosett Max | Chief Financial Officer | Sell | 60,000 | $18.23 | $1.1M | 54,037 | +1.13% | -1.77% |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | — | Buy | 1,000 | $19.27 | $19K | 43,415 | -1.25% | -0.89% |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | — | Buy | 3,500 | $19.46 | $68K | 42,415 | -1.25% | -0.89% |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | — | Buy | 6,000 | $19.48 | $117K | 38,915 | -1.25% | -0.89% |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | — | Sell | 10,000 | $19.41 | $194K | 32,915 | -1.25% | -0.89% |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | — | Sell | 500 | $19.44 | $10K | 42,915 | -1.25% | -0.89% |
| May 15, 2026 | BIENAIME JEAN JACQUES | — | Buy | 5,000 | $20.70 | $104K | 43,415 | +9.51% | +0.91% |
8-K · 2.02
!! High
Immunome, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K
Immunome, Inc. -- 8-K Filing
Immunome reported 2025 full-year financial results and provided a business update on its pipeline of targeted cancer therapies, though specific revenue or clinical milestone details require review of the complete filing.
Mar 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 16,969,954 | $371M | Added | Mar 2026 |
| 2 | Blackrock, Inc. | 8,805,492 | $187M | New | Jun 2026 |
| 3 | Primecap Management Co/ca/ | 4,788,231 | $105M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 4,551,289 | $96M | Added | Jun 2026 |
| 5 | Morgan Stanley | 3,418,178 | $73M | Reduced | Dec 2025 |
| 6 | Jpmorgan Chase & Co | 2,777,836 | $54M | Reduced | Mar 2026 |
| 7 | Woodline Partners Lp | 1,575,398 | $34M | — | Mar 2026 |
| 8 | Marshall Wace, Llp | 1,480,788 | $32M | Added | Mar 2026 |
| 9 | Principal Financial Group Inc | 1,404,450 | $30M | Added | Dec 2025 |
| 10 | Vanguard Portfolio Management Llc | 1,348,979 | $29M | Added | Jun 2026 |
| 11 | Bnp Paribas Asset Management Holding S.a. | 1,250,275 | $26M | Added | Jun 2026 |
| 12 | Silverarc Capital Management, Llc | 1,126,210 | $24M | New | Dec 2025 |
| 13 | Northern Trust Corp | 899,146 | $20M | Added | Mar 2026 |
| 14 | Metlife Investment Management, Llc | 859,076 | $18M | New | Jun 2026 |
| 15 | Janus Henderson Group Plc | 808,019 | $18M | New | Mar 2026 |
| 16 | Bank Of America Corp /de/ | 781,607 | $17M | Added | Mar 2026 |
| 17 | Td Asset Management Inc | 719,272 | $15M | New | Jun 2026 |
| 18 | Nan Fung Trinity (Hk) Ltd | 714,553 | $15M | — | Jun 2026 |
| 19 | Candriam S.c.a. | 539,882 | $12M | Reduced | Dec 2025 |
| 20 | Citadel Advisors Llc | 448,158 | $9M | Added | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.25B
Enterprise Value
$1.60B
P/E (TTM)
-10.14x
Forward P/E
—
PEG Ratio
0.17x
P/B
3.55x
P/S
—
P/FCF
-11.21x
EV/EBITDA
—
Shares Out
87.4M
Financials (TTM)
Revenue
$0
Net Income
-$254.3M
EBITDA
-$251.2M
Free Cash Flow
-$200.6M
Op Cash Flow
-$190.9M
EPS Basic
$-2.43
EPS Diluted
$-2.54
EPS Forward
$-2.40
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$683.2M
Total Liab.
$48.8M
Total Equity
$634.3M
Cash
$653.5M
LT Debt
$3.9M
Book Value/Sh
$7.26
Debt/Equity
0.01x
Current Ratio
14.69
Quick Ratio
14.69
Returns & Growth
ROE
-33.5%
ROA
-31.1%
ROIC
-33.6%
Rev Growth YoY
-23.2%
EPS Growth YoY
+51.4%
Price Returns
2W
-6.3%
1M
-12.1%
3M
+30.7%
6M
+25.3%
12M
+156.6%
Technicals
52W High
$29.83
52W Low
$9.77
50d MA
$25.36
200d MA
$22.69
RSI (14)
39.90
ATR (14)
$1.07
Beta
2.14
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$36.83
High
$40.00
Low
$32.00
Median
$38.00
Data updated apr 25, 2026 3:19pm
· Source: financialmodelingprep.com